Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects

NCT01516307 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

349

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

BIOLOGICAL: OPT-822/OPT-821(30 μg/100 μg)
BIOLOGICAL: Phosphate Buffer Saline (PBS)
DRUG: Cyclophosphamide

Sponsor

OBI Pharma, Inc